With a decision from the FDA for its use in moderate-to-severe asthma expected by the end of the week, the biologic dupilumab showed positive results from a pivotal phase 3 trial for inadequately ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...

The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis. Treatment with benralizumab was associated ...

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...

DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with ...

With a high recurrence rate following surgery to treat chronic sinusitis with nasal polyps, authors set out to investigate the effectiveness and safety of endoscopic sinus surgery (ESS) in a pediatric ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Please provide your email address to receive an email when new articles are posted on . IL-4, IL-5 and IL-13 cytokines characterize the type 2 inflammatory signature found in most patients with CRSwNP ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline data from two Phase III multicenter studies ...

GlaxoSmithKline announced that the FDA has approved Nucala as a treatment for adults who have chronic rhinosinusitis with nasal polyps. Nucala (mepolizumab) is a monoclonal antibody that inhibits ...